Immune activation in patients with locally advanced cervical cancer treated with ipilimumab following definitive chemoradiation (GOG-9929)

PURPOSE: A Phase I clinical trial (GOG-9929) examined the safety and efficacy of adjuvant immune modulation therapy with the checkpoint inhibitor ipilimumab (anti-CTLA4) following chemoradiation therapy (CRT) for newly diagnosed node-positive human papillomavirus (HPV)-related cervical cancer. To be...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Clin Cancer Res
Glavni autori: DA SILVA, Diane M., ENSERRO, Danielle M., MAYADEV, Jyoti S., SKEATE, Joseph G., MATSUO, Koji, PHAM, Huyen Q., LANKES, Heather A., MOXLEY, Katherine M., GHAMANDE, Sharad A., LIN, Yvonne G., SCHILDER, Russell J., BIRRER, Michael J., KAST, W. Martin
Format: Artigo
Jezik:Inglês
Izdano: 2020
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7642021/
https://ncbi.nlm.nih.gov/pubmed/32816895
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-20-0776
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items